TEZSPIRE Market Size, Insight, and Forecast to 2032

This report provides comprehensive insights about TEZSPIRE for Asthma in the seven major markets. A detailed picture of the TEZSPIRE for Asthma in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019-2032 is provided in this report along with a detailed description of the TEZSPIRE for Asthma.

The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the TEZSPIRE market forecast analysis for Asthma in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in Asthma.

Drug Summary

TEZSPIRE (tezepelumab) was developed by AstraZeneca in collaboration with Amgen as a first-in-class human monoclonal antibody that inhibits the action of TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and is critical in the initiation and persistence of allergic, eosinophilic and other types of airway inflammation associated with severe asthma, including airway hyper responsiveness.

Blocking TSLP with tezepelumab-ekko reduces inflammation-related biomarkers and cytokines, including blood eosinophils, airway submucosal eosinophils, IgE, FeNO, IL-5, and IL-13; however, the mechanism of tezepelumab-ekko action in asthma has not been definitively established.

TEZSPIRE is approved in the US, EU, Japan, and other countries for treating severe asthma. TEZSPIRE is also developing for other potential indications, including chronic obstructive pulmonary disease (COPD), chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, and eosinophilic esophagitis (EoE).

Dosage and administration

The recommended dosage of TEZSPIRE is 210 mg, administered subcutaneously once every 4 weeks. Administer the dose as soon as possible in case missed. After that, the patient can continue (resume) dosing on the usual administration day. If the next dose is already due, then administer it as planned. TEZSPIRE is intended for administration by a healthcare provider.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the TEZSPIRE description, mechanism of action, dosage and administration, research and development activities in Asthma.
• Elaborated details on TEZSPIRE regulatory milestones and other development activities have been provided in this report.
• The report also highlights the TEZSPIRE research and development activities in Asthma across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around TEZSPIRE.
• The report contains forecasted sales of TEZSPIRE for Asthma till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Asthma.
• The report also features the SWOT analysis with analyst views for TEZSPIRE in Asthma.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

TEZSPIRE Analytical Perspective

In-depth TEZSPIRE Market Assessment

This report provides a detailed market assessment of TEZSPIRE for Asthma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

TEZSPIRE Clinical Assessment

The report provides the clinical trials information of TEZSPIRE for Asthma covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Asthma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TEZSPIRE dominance.
• Other emerging products for Asthma are expected to give tough market competition to TEZSPIRE and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TEZSPIRE in Asthma.
• This in-depth analysis of the forecasted sales data of TEZSPIRE from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the TEZSPIRE in Asthma.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of TEZSPIRE?
• What is the clinical trial status of the study related to TEZSPIRE in Asthma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TEZSPIRE development?
• What are the key designations that have been granted to TEZSPIRE for Asthma?
• What is the forecasted market scenario of TEZSPIRE for Asthma?
• What are the forecasted sales of TEZSPIRE in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to TEZSPIRE for Asthma?
• Which are the late-stage emerging therapies under development for the treatment of Asthma?

This product will be delivered within 2 business days.